BRAF — Targeted Therapies, Trials & Pipeline

BRAF V600 mutations activate MAPK signaling in melanoma, NSCLC, thyroid and colorectal cancer; treated with BRAF ± MEK inhibition.

Approved drugs targeting BRAF

Landmark trials